#4 - Novartis (NYSE:NVS)
Novartis AG (NYSE: NVS) stock is showing modest growth in 2024. Shares are up 14% for the year and have risen a brisk 21% in the six months ending September 26, 2024.
The thesis for Novartis is similar to the other biopharmaceutical companies. It has several commercial drugs facing patent expiration. But it also has a strong pipeline. One of the company’s most exciting treatments in late-stage clinical trials is Kesmipta (ofatumumab), which is a treatment for patients with relapsing multiple sclerosis (MS). The company recently received positive clinical data showing that most patients showed no disability progression for up to six years.
NVS stock hasn’t been a blockbuster stock with a return of around 37% in the last five years. The company’s own internal forecasting suggests investors should expect comparable growth in the next year or so. But in a market that may remain volatile, Novartis is likely to deliver a slow, steady return that should reward less risk-tolerant investors.
About Novartis
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.
Read More - Current Price
- $115.61
- Consensus Rating
- Reduce
- Ratings Breakdown
- 0 Buy Ratings, 7 Hold Ratings, 1 Sell Ratings.
- Consensus Price Target
- $120.70 (4.4% Upside)
